๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

โœ Scribed by Helena R. Chang

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
348 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Adjuvant trastuzumab with chemotherapy i
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
โœ Heather L. McArthur; Kathleen M. Mahoney; Patrick G. Morris; Sujata Patil; Linds ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 243 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND: Several large, randomized trials established the benefits of adjuvant trastuzumab with chemotherapy. However, the benefit for women with small, nodeโ€negative HER2โ€positive (HER2+) disease is unknown, as these patients were largely excluded from these trials. Therefore, a

Quantitative HER2 protein levels predict
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab
โœ Allan Lipton; Wolfgang J. Kรถstler; Kim Leitzel; Suhail M. Ali; Jeff Sperinde; Jo ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 492 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND: Only a portion of breast cancer patients currently selected for trastuzumab therapy respond. ## METHODS: Using a novel assay (HERmark) to quantify total human epidermal growth factor receptor 2 (HER2) expression, the authors examined outcomes in 102 trastuzumabโ€treated

Her-2/neu and EGFR tyrosine kinase activ
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer
โœ Gernot Hudelist; Wolfgang J. Kรถstler; Klaus Czerwenka; Ernst Kubista; Johannes A ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 372 KB ๐Ÿ‘ 1 views

## Abstract Herโ€2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the antiโ€Herโ€2/__neu__ antibody trastuzumab (Herceptinยฎ) has become a valuable therapeutic option for patients with Herโ€2/__neu__โ€overexpressing breast cancer, man